Macleods Pharmaceuticals Limited and Hikma Pharmaceuticals received FDA approval for their generic chlorthalidone ANDA on July 1, 2026, which is expected to assert significant market pricing pressure following a top-30 patent expiration for the brand. This approval enters a crowded generic space sustained by subsequent ANDA filers, necessitating Macleods to compete aggressively on value to capture market share against entrenched incumbents.